We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.
We currently have one development programme (Chk1) in two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programme (Aurora+FLT3) is in preclinical development.